Sertoli cell therapy: A novel possible treatment strategy for treatment-resistant major depressive disorder

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

By the year 2020, depression will be the 2nd most common health problem in the world. Current medications to treat depression are effective in less than 50% of patients. There is the need for novel treatments for depression to address the high rates of resistance to current treatment and the chronic residual symptoms in many patients treated for depression. The heterogeneity of major depressive disorder suggests that multiple neurocircuits and neurochemicals are involved in its pathogenesis thus, finding an alternative to neurotransmitter agonist- or antagonist-based treatments offers an important new approach. Cellular therapy is an emerging treatment strategy for multiple diseases, including depression. Based upon their in vivo function as "nurse cells" within the testis and the documented viability, efficacy, and safety of Sertoli cells transplanted into multiple tissues, including brain, the potential for these cells to provide a neuroprotective, anti-inflammatory, and trophic environment for neurons should be considered. It is proposed that the combination of self-protective, immunoregulatory and trophic properties of Sertoli cells may confer a unique potential for depression treatment and avoid many of the risks and challenges associated with stem cell therapies. At the very least, studies of the effects of Sertoli cell transplantation will add substantially to our understanding of the cellular and molecular processes that underlie depression.

Original languageEnglish (US)
Pages (from-to)35-42
Number of pages8
JournalMedical Hypotheses
Volume77
Issue number1
DOIs
StatePublished - Jul 2011

Fingerprint

Treatment-Resistant Depressive Disorder
Sertoli Cells
Major Depressive Disorder
Cell- and Tissue-Based Therapy
Depression
Therapeutics
Cell Transplantation
Neurotransmitter Agents
Testis
Anti-Inflammatory Agents
Stem Cells
Nurses
Safety
Neurons
Health
Brain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sertoli cell therapy : A novel possible treatment strategy for treatment-resistant major depressive disorder. / Loftis, Jennifer.

In: Medical Hypotheses, Vol. 77, No. 1, 07.2011, p. 35-42.

Research output: Contribution to journalArticle

@article{150942722c5e4d45b03b1ed749fc805c,
title = "Sertoli cell therapy: A novel possible treatment strategy for treatment-resistant major depressive disorder",
abstract = "By the year 2020, depression will be the 2nd most common health problem in the world. Current medications to treat depression are effective in less than 50{\%} of patients. There is the need for novel treatments for depression to address the high rates of resistance to current treatment and the chronic residual symptoms in many patients treated for depression. The heterogeneity of major depressive disorder suggests that multiple neurocircuits and neurochemicals are involved in its pathogenesis thus, finding an alternative to neurotransmitter agonist- or antagonist-based treatments offers an important new approach. Cellular therapy is an emerging treatment strategy for multiple diseases, including depression. Based upon their in vivo function as {"}nurse cells{"} within the testis and the documented viability, efficacy, and safety of Sertoli cells transplanted into multiple tissues, including brain, the potential for these cells to provide a neuroprotective, anti-inflammatory, and trophic environment for neurons should be considered. It is proposed that the combination of self-protective, immunoregulatory and trophic properties of Sertoli cells may confer a unique potential for depression treatment and avoid many of the risks and challenges associated with stem cell therapies. At the very least, studies of the effects of Sertoli cell transplantation will add substantially to our understanding of the cellular and molecular processes that underlie depression.",
author = "Jennifer Loftis",
year = "2011",
month = "7",
doi = "10.1016/j.mehy.2011.03.017",
language = "English (US)",
volume = "77",
pages = "35--42",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Sertoli cell therapy

T2 - A novel possible treatment strategy for treatment-resistant major depressive disorder

AU - Loftis, Jennifer

PY - 2011/7

Y1 - 2011/7

N2 - By the year 2020, depression will be the 2nd most common health problem in the world. Current medications to treat depression are effective in less than 50% of patients. There is the need for novel treatments for depression to address the high rates of resistance to current treatment and the chronic residual symptoms in many patients treated for depression. The heterogeneity of major depressive disorder suggests that multiple neurocircuits and neurochemicals are involved in its pathogenesis thus, finding an alternative to neurotransmitter agonist- or antagonist-based treatments offers an important new approach. Cellular therapy is an emerging treatment strategy for multiple diseases, including depression. Based upon their in vivo function as "nurse cells" within the testis and the documented viability, efficacy, and safety of Sertoli cells transplanted into multiple tissues, including brain, the potential for these cells to provide a neuroprotective, anti-inflammatory, and trophic environment for neurons should be considered. It is proposed that the combination of self-protective, immunoregulatory and trophic properties of Sertoli cells may confer a unique potential for depression treatment and avoid many of the risks and challenges associated with stem cell therapies. At the very least, studies of the effects of Sertoli cell transplantation will add substantially to our understanding of the cellular and molecular processes that underlie depression.

AB - By the year 2020, depression will be the 2nd most common health problem in the world. Current medications to treat depression are effective in less than 50% of patients. There is the need for novel treatments for depression to address the high rates of resistance to current treatment and the chronic residual symptoms in many patients treated for depression. The heterogeneity of major depressive disorder suggests that multiple neurocircuits and neurochemicals are involved in its pathogenesis thus, finding an alternative to neurotransmitter agonist- or antagonist-based treatments offers an important new approach. Cellular therapy is an emerging treatment strategy for multiple diseases, including depression. Based upon their in vivo function as "nurse cells" within the testis and the documented viability, efficacy, and safety of Sertoli cells transplanted into multiple tissues, including brain, the potential for these cells to provide a neuroprotective, anti-inflammatory, and trophic environment for neurons should be considered. It is proposed that the combination of self-protective, immunoregulatory and trophic properties of Sertoli cells may confer a unique potential for depression treatment and avoid many of the risks and challenges associated with stem cell therapies. At the very least, studies of the effects of Sertoli cell transplantation will add substantially to our understanding of the cellular and molecular processes that underlie depression.

UR - http://www.scopus.com/inward/record.url?scp=79958047244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958047244&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2011.03.017

DO - 10.1016/j.mehy.2011.03.017

M3 - Article

C2 - 21454019

AN - SCOPUS:79958047244

VL - 77

SP - 35

EP - 42

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 1

ER -